PTC THERAPEUTICS, INC. (NASDAQ:PTCT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 18, 2017, Dr. C. Geoffrey McDonough, a member of the board of directors (the “Board”) of PTC Therapeutics, Inc. (the “Company”), notified the Company of his resignation from the Board effective immediately. Dr. McDonough has informed the Company that his decision is based on his need to focus on commitments to his principal work activities and was not due to any disagreement with the Company.
The Company and Dr. McDonough entered into a consulting agreement (the “Consulting Agreement”) for Dr. McDonough to remain as an advisor to the Company, effective as of September 18, 2017, with a term continuing through March 18, 2018. to the Consulting Agreement, Dr. McDonough will receive an hourly consulting fee of $292. Certain of Dr. McDonough’s restricted stock awards and stock options will continue to vest and be eligible to be exercised in accordance with Schedule A of the Consulting Agreement. The foregoing description of the Consulting Agreement, which is filed herewith as Exhibit10.1 and is incorporated herein by reference, is qualified in its entirety by reference to its terms.
|
Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits
|
Exhibit No. |
Description |
|
Consulting Services Agreement between the Registrant and Dr. C. Geoffrey McDonough |
PTC THERAPEUTICS, INC. ExhibitEX-10.1 2 ex101mcdonoughconsultagmt.htm EXHIBIT 10.1 Exhibit PTC Services Agreement PTC CONSULTING SERVICES AGREEMENT This Consulting Services Agreement (together with all attachments hereto,…To view the full exhibit click here
About PTC THERAPEUTICS, INC. (NASDAQ:PTCT)
PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company’s lead product, Translarna (ataluren), is used for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients with age of over five years and older. Its programs include Translarna for nonsense mutation cystic fibrosis (nmCF), Translarna for mucopolysaccharidosis type I caused by nonsense mutation (nmMPS I), Translarna for nonsense mutation aniridia, Translarna for nonsense mutation Dravet syndrome/CDKL5, Spinal muscular atrophy (SMA) in collaboration with Spinal Muscular Atrophy Foundation (SMA Foundation) and F. Hoffman-La Roche Ltd and Hoffman- La Roche Inc. (collectively Roche), and Cancer stem cell program (PTC596). It has two compounds in clinical development within the SMA program: RG7800 and RG7916.
